2d illustrations and photos/iStock via Getty Images
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering.
In a recent SEC filing, Metsera (MTSR) said it was looking to offer 17.2M shares priced between $15